Primary peripheral T‐cell lymphoma, not otherwise specified of the thyroid with autoimmune thyroiditis

Abstract

Summary Primary peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS) of the thyroid is an extremely rare neoplasm. Six cases of primary PTCL‐NOS of the thyroid were analysed for clinicopathological features and genomic alteration patterns using oligo‐array comparative genomic hybridization. All patients had a diffusely enlarged thyroid and three cases showed leukaemic manifestation. Five of the six cases had anti‐thyroid antibodies and the remaining case showed hypothyroidism, suggesting that all cases had autoimmune thyroiditis. Except for one early relapsed case, the remaining five patients are alive and three of these five individuals have survived for 70 months or more. Interestingly, two cases showed spontaneous regressions after partial thyroid biopsy without any therapy. Leukaemic manifestation disappeared after irradiation of the thyroid mass in another two cases. The tumour cells were positive for CD3, CD4 and CXCR3 in all cases, suggesting that the tumour cells are of a type 1 helper T‐cell origin. All six cases showed genomic alterations that were different from those previously reported for PTCL‐NOS. The loss of 6q24·2 was characteristic and was detected in four of the six cases. These results suggest that primary PTCL‐NOS of the thyroid arising from autoimmune thyroiditis is a distinct disease entity among heterogeneous PTCL‐NOS.

Molecular Characterization of Chronic-type Adult T-cell Leukemia/Lymphoma

“…agilent.com). Raw data were transferred to the Genomic Workbench v5.0 software (Agilent Technologies) for further analysis as described previously (14)(15)(16). Among these identified alterations, we focused on minimal common regions (MCR).…”

“…MCRs are defined as alterations that encompass less than 3 protein-coding genes among all samples analyzed in this study (17). Copy number variations/polymorphisms (CNV) were identified using a database (HS_hg18_CNV-20120403, Agilent), which was obtained from Database of Genomic Variants (http://projects.tcag.ca/variation/) in April 2012 and then excluded from further analyses as described previously (16). We also performed aCGH analysis on matched normal DNA samples that were available and confirmed that the identified MCRs were not CNVs (Supplementary Fig.…”

“…The total RNA of 13 chronic samples and 21 acute samples was analyzed. The experimental protocol used reflected the manufacturer's protocol (www.agilent.com) as previously reported (15,16). Using the results of GEP, gene set enrichment analysis (GSEA) was performed as previously described (15,16,18).…”

STX11 functions as a novel tumor suppressor gene in peripheral T‐cell lymphomas

“…The Institute Review Board of the Aichi Cancer Center approved all the samples and medical records used in our study. Most patients with PTCL‐NOS and PTTL were treated with anthracycline‐based chemotherapy, as previously reported . Clinicopathological findings were reexamined from the results of previous our studies .…”

“…We previously analyzed the genomic alterations associated with primary T‐cell lymphoma of the thyroid (primary thyroid T‐cell lymphoma [PTTL]) . In that study, we observed that 67% of PTTL cases showed genomic loss at 6q24.2.…”